WO2007076091A3 - Treatment of viral infections using a tissue factor inhibitor - Google Patents

Treatment of viral infections using a tissue factor inhibitor Download PDF

Info

Publication number
WO2007076091A3
WO2007076091A3 PCT/US2006/049185 US2006049185W WO2007076091A3 WO 2007076091 A3 WO2007076091 A3 WO 2007076091A3 US 2006049185 W US2006049185 W US 2006049185W WO 2007076091 A3 WO2007076091 A3 WO 2007076091A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
viral infections
tissue factor
factor inhibitor
inhibitor
Prior art date
Application number
PCT/US2006/049185
Other languages
French (fr)
Other versions
WO2007076091A2 (en
Inventor
Sek Chung Michael Fung
Original Assignee
Genentech Inc
Sek Chung Michael Fung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Sek Chung Michael Fung filed Critical Genentech Inc
Publication of WO2007076091A2 publication Critical patent/WO2007076091A2/en
Publication of WO2007076091A3 publication Critical patent/WO2007076091A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

The present invention provides novel methods for the treatment of viral infections, such as influenza virus both human and avian, by administering a tissue factor inhibitor.
PCT/US2006/049185 2005-12-22 2006-12-21 Treatment of viral infections using a tissue factor inhibitor WO2007076091A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US75297205P 2005-12-22 2005-12-22
US60/752,972 2005-12-22
US75805706P 2006-01-11 2006-01-11
US60/758,057 2006-01-11

Publications (2)

Publication Number Publication Date
WO2007076091A2 WO2007076091A2 (en) 2007-07-05
WO2007076091A3 true WO2007076091A3 (en) 2008-10-09

Family

ID=38218698

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2006/049185 WO2007076091A2 (en) 2005-12-22 2006-12-21 Treatment of viral infections using a tissue factor inhibitor
PCT/US2006/049186 WO2008030260A2 (en) 2005-12-22 2006-12-21 Treatment of variola viral infections using a tissue factor inhibitor

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2006/049186 WO2008030260A2 (en) 2005-12-22 2006-12-21 Treatment of variola viral infections using a tissue factor inhibitor

Country Status (1)

Country Link
WO (2) WO2007076091A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA109633C2 (en) 2008-12-09 2015-09-25 HUMAN ANTIBODY AGAINST TISSUE FACTOR
JP6055404B2 (en) 2010-06-15 2016-12-27 ゲンマブ エー／エス Human antibody drug conjugates against tissue factor
WO2016098904A1 (en) * 2014-12-19 2016-06-23 国立大学法人 長崎大学 Novel bisphosphonic acid derivative and application for same
US10430534B2 (en) * 2016-11-30 2019-10-01 Numem Inc. Resistance-based memory compiler
US20230218548A1 (en) * 2020-03-19 2023-07-13 Eumentis Therapeutics, Inc. Nitro-aminoadamantane compounds for the treatment of betacoronavirus infections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266672A1 (en) * 2003-05-06 2004-12-30 Vlasuk George P Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
US20050089929A1 (en) * 1997-03-10 2005-04-28 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20050169927A1 (en) * 2001-10-02 2005-08-04 Novo Nordisk A/S Human tissue factor antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5589173A (en) * 1986-11-04 1996-12-31 Genentech, Inc. Method and therapeutic compositions for the treatment of myocardial infarction
US6593291B1 (en) * 1997-02-06 2003-07-15 Entremed, Inc. Compositions and methods of use of ligands that bind components of the blood coagulation/clotting pathway for the treatment of cancer and angiogenic-based disease
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
EP1223921A2 (en) * 1999-10-27 2002-07-24 Sunol Molecular Corporation Tissue factor antagonists and methods of use thereof
WO2005065678A1 (en) * 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089929A1 (en) * 1997-03-10 2005-04-28 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20050169927A1 (en) * 2001-10-02 2005-08-04 Novo Nordisk A/S Human tissue factor antibodies
US20040266672A1 (en) * 2003-05-06 2004-12-30 Vlasuk George P Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BOUWMAN ET AL.: "Procoagulant and inflammatory response of virus-infected monocyte", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 32, no. 10, October 2002 (2002-10-01), pages 759 - 766 *
GIRARD ET AL.: "Endogenous phosphorylation of the lipoprotein-associated coagulation inhibitor at serine-2", THE BIOCHEMICAL JOURNAL, vol. 270, no. 3, September 1990 (1990-09-01), pages 621 - 625 *
MCKIMM-BRESHKIN J.L.: "Neuraminidase inhibitors for the treatment and prevention of influenza", EXPERT OPINION ON PHARMACOLOGY, vol. 3, no. 2, February 2002 (2002-02-01), pages 103 - 112 *
SUTHERLAND ET AL.: "Coagulation initiated on herpesviruses", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 94, no. 25, 1997, pages 13510 - 13514 *
VISSEREN ET AL.: "Interleukin-6 production by endothelial cells after infection with influenza virus and cytomegalovirus", JOURNAL OF LABORATORY AND CLINICAL MEDICINE, vol. 134, no. 6, December 1999 (1999-12-01), pages 623 - 630 *
VISSEREN ET AL.: "Procoagulant activity of endothelial cells after infection with respiratory viruses", THROMBOSIS AND HAEMOSTASIS, vol. 84, no. 2, August 2000 (2000-08-01), pages 319 - 324 *

Also Published As

Publication number Publication date
WO2007076091A2 (en) 2007-07-05
WO2008030260A2 (en) 2008-03-13
WO2008030260A3 (en) 2008-06-26

Similar Documents

Publication Publication Date Title
WO2007030810A3 (en) Multiparameter whole blood monitor and method
EP1865967A4 (en) Compounds, compositions and methods for the treatment of viral infections and other medical disorders
WO2008127364A3 (en) Antiviral compounds and use thereof
MY141003A (en) Materials and methods for treating viral infections with a cysteamine compound
TN2010000137A1 (en) Spiropyrrolidines and their use against hcv and hiv infection
WO2007084413A3 (en) Methods for treating hepatitis c
BRPI1013394A2 (en) "compound, pharmaceutical composition, use of the compound, and method for treating a hepatitis c virus infected patient."
EA201070794A1 (en) Recombinant antigens RSV
WO2007084435A3 (en) Methods for treating hepatitis c
WO2007041487A3 (en) Viral peptides and their use to inhibit viral infections against viruses of the flaviridae family
NO20085243L (en) Pharmaceutical composition for the treatment of viral infections and / or tumor diseases through inhibition of protein folding and protein degradation
BRPI0916235A2 (en) compound, pharmaceutical composition, use of the compound or composition, and method for treating an hcv infected patient
WO2008115281A3 (en) Compounds for treating viral infections
WO2010003313A8 (en) Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
WO2007133865A3 (en) Hcv/hiv inhibitors an their uses
WO2007120595A3 (en) Amines for the treatment of hcv
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2011150190A3 (en) Hcv inhibitor compounds and methods of use thereof
NO20053348D0 (en) Pharmaceutical composition for the treatment of viral attacks.
IL202450A (en) Pharmaceutical composition for the treatment of an influenza virus infection
EA201170605A1 (en) CYCLONE DECADEPSYPE COMPOUNDS AND APPLICATION OF THE SPECIFIED COMPOUNDS AS A MEDICINE
WO2012061248A3 (en) Novel specific hcv ns3 protease inhibitors
WO2007002639A3 (en) Non-nucleoside anti-hepacivirus agents and uses thereof
WO2007076091A3 (en) Treatment of viral infections using a tissue factor inhibitor
WO2011056630A3 (en) Small molecule inhibitors of hepatitis c virus

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06848932

Country of ref document: EP

Kind code of ref document: A2